Abstract
Burn injury in children triggers a series of nonspecific adaptive responses. Among them are the systemic inflammatory response and the stress response, as well as a consequent period of relative immobilization. It is likely that both the systemic inflammatory response through the production of cytokines and the stress response, through the production of endogenous glucocorticoids, stimulate acute bone loss by means of excess bone resorption followed by osteoblastic apoptosis caused by the endogenous glucocorticoids, which make it impossible to repair the bone loss by making new bone. In this chapter we describe two studies that demonstrate that the acute administration of the antiresorptive bisphosphonate pamidronate is able to not only prevent the acute post-burn bone loss but also permit continued new bone mass accretion with time. The lack of side effects suggests that this drug can be used both safely and effectively in pediatric burn patients to prevent bone loss and the manner of its successful use may have applications to other pediatric conditions, which will be discussed.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Klein GL, Herndon DN, Goodman WG, Langman CB, Phillips WA, Dickson IR, et al. Histomorphometric and biochemical characterization of bone following acute severe burns in children. Bone. 1995;17:455–60.
Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell. 1998;93:165–76.
Takeda S, Elefteriou F, Levasseur R, Liu X, Zhao L, Parker KL, et al. Leptin regulates bone formation via the sympathetic nervous system. Cell. 2002;111:305–17.
Klein GL, Bi LX, Sherrard DJ, Beavan SR, Ireland D, Compston JE, et al. Evidence supporting a role of glucocorticoids in short-term bone loss in burned children. Osteoporos Int. 2004;15:468–74.
Klein GL, Herndon DN, Rutan TC, Sherrard DJ, Coburn JW, Langman CB, et al. Bone disease in burn patients. J Bone Miner Res. 1993;8:337–45.
Baer LA, Wu X, Tou JC, Johnson E, Wolf SE, Wade CE. Contribution of severe burn and disuse to bone structure and strength in rats. Bone. 2013;52:644–50.
Rodriguez N, Herndon DN, Klein GL. Evidence against immobilization in the bone loss following burns [Abstract]. Bone. 2011;48 Suppl 2:S190.
Leblebici B, Sezgin N, Ulusan SN, Tarim AN, Akman MN, Haberal MA. Bone loss during the acute stage following burn injury. J Burn Care Res. 2008;29:763–7.
Klein GL, Herndon DN, Langman CB, Rutan TC, Young WE, Pembleton G, et al. Long-term reduction in bone mass after severe burn injury in children. J Pediatr. 1995;126:252–6.
Klein GL, Nicolai M, Langman CB, Cuneo BF, Sailer DE, Herndon DN. Dysregulation of calcium homeostasis after severe burn injury in children. J Pediatr. 1997;131:246–51.
Murphey ED, Chattopadhyay N, Bai M, Kifor O, Harper D, Traber DL, et al. Up-regulation of the parathyroid calcium-sensing receptor after burn injury in sheep: a potential contributing factor to post-burn hypocalcemia. Crit Care Med. 2000;28:3885–90.
Rutan RL, Herndon DN. Growth delay in post-burn pediatric patients. Arch Surg. 1990;125:392–5.
Russell RGG. Bisphosphonates: mode of action and pharmacology. Pediatrics. 2007;119 Suppl 2:S150–62.
Klein GL, Wimalawansa SJ, Kulkarni G, Sherrard DJ, Sanford AP, Herndon DN. The efficacy of acute administration of pamidronate on the conservation of bone mass following acute severe burn injury in children. Osteoporos Int. 2005;16:631–5.
Przkora R, Herndon DN, Sherrard DJ, Chinkes DL, Klein GL. Pamidronate preserves bone mass for at least 2 years following acute administration for pediatric burn injury. Bone. 2007;41:297–302.
Plotkin LI, Weinstein RS, Parfitt AM, Roberson PK, Manolagas SC, Belllido T. Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin. J Clin Invest. 1999;104:1363–74.
Hart DW, Herndon DN, Klein G, Lee SB, Celis M, Mohan S, et al. Attenuation of post-traumatic muscle catabolism and osteopenia by long-term growth hormone therapy. Ann Surg. 2001;233:827–34.
Rodd C, Lang B, Ramsay T, Alos N, Huber AM, Cabral DA, Canadian Steroid-Associated Osteoporosis in the Pediatric Population (STOPP) Consortium, et al. Incident vertebral fractures among children with rheumatic disorders 12 months after glucocorticoid initiation: a national observational study. Arthritis Care Res. 2012;64:122–31.
Nakhia M, Denker AE, Connor JD, Carpenter TO, Walson PD, Porras AG, et al. Bioavailability and short-term tolerability of alendronate in glucocorticoid-treated children. Clin Ther. 2011;33:1516–23.
Mitterbauer C, Schwarz C, Haas M, Oberbauer R. Effects of bisphosphonates on bone loss in the first year after renal transplantation- a meta analysis of randomized controlled trials. Nephrol Dial Transplant. 2006;21:2275–81.
Torregrosa JV, Fuster D, Monegal A, Gentil MA, Bravo J, Guirado L, et al. Efficacy of low doses of pamidronate in osteopenic patients administered early in the post-renal transplant. Osteoporos Int. 2011;22:281–7.
Bachrach LK, Ward LM. Clinical review 1: Bisphosphonate use in childhood osteoporosis. J Clin Endocrinol Metab. 2009;94:400–9.
Acknowledgements
The author acknowledges grant support from the Shriners Hospitals for Children (SHC 8640) and from the National Institutes of Health (1P50 GM 60338) for the conduct of the studies described in this chapter. The author also expresses gratitude for the technical assistance provided by the personnel of the Clinical Research Core of the Shriners Hospital for Children Galveston, and furthermore discloses that he served on the Bone Toxicity Advisory Board of Novartis Pharmaceuticals in August 2012.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer Science+Business Media New York
About this chapter
Cite this chapter
Klein, G.L. (2014). Bisphosphonates in Pediatric Burn Injury. In: Klein, G. (eds) Bone Drugs in Pediatrics. Springer, Boston, MA. https://doi.org/10.1007/978-1-4899-7436-5_7
Download citation
DOI: https://doi.org/10.1007/978-1-4899-7436-5_7
Published:
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4899-7435-8
Online ISBN: 978-1-4899-7436-5
eBook Packages: MedicineMedicine (R0)